Advertisement
Advertisement
U.S. Markets close in 1 hr 9 mins
Advertisement
Advertisement
Advertisement
Advertisement

Aquestive Therapeutics, Inc. (AQST)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.8780-0.0086 (-0.97%)
As of 02:36PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8866
Open0.9000
Bid0.8791 x 1000
Ask0.8781 x 800
Day's Range0.8701 - 0.9099
52 Week Range0.6180 - 3.1900
Volume88,586
Avg. Volume266,673
Market Cap35.264M
Beta (5Y Monthly)3.02
PE Ratio (TTM)N/A
EPS (TTM)-1.6580
Earnings DateMar 06, 2023 - Mar 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.36
  • Simply Wall St.

    When Will Aquestive Therapeutics, Inc. (NASDAQ:AQST) Breakeven?

    With the business potentially at an important milestone, we thought we'd take a closer look at Aquestive Therapeutics...

  • GlobeNewswire

    Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

    Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of 2023 Anticipates receipt in the coming months of FDA response to request for Libervant™ (diazepam) Buccal Film accelerated market access Expects preliminary unaudited cash and cash equivalents of approximately $27 million as of December 31, 2022 WARREN, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceu

  • GlobeNewswire

    Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

    FDA continues to indicate that the Company can conduct a comparability study rather than efficacy studiesFDA provides clear guidance on approvability expectations for pharmacokinetic (PK) performance and patient administration attributesCompany continues to anticipate a potential product launch in 2025 with an NDA submission in first half of 2024 WARREN, N.J., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company ad

Advertisement
Advertisement